RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus.

RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. Abstract Text:

C J Fuller,M Chandalia,A Garg,S M Grundy,I Jialal,

Patients with diabetes mellitus have an increased risk of premature atherosclerosis, which may be due in part to increased oxidizability of low-density lipoprotein (LDL). Numerous studies have shown that alpha-tocopherol can reduce the oxidative susceptibility of LDL in normoglycemic subjects; however, there are few studies in persons with diabetes. In addition, alpha-tocopherol may reduce the extent of protein glycation. Therefore, the objective of the present study was to assess the effect of RRR-alpha-tocopheryl acetate supplementation on LDL oxidizability and protein glycation in persons with diabetes without evidence of vascular disease. Twenty-eight persons with insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) were randomly assigned to receive either placebo or 1632 mg (1200 IU) RRR-alpha-tocopherol/d, as tocopheryl acetate, for 8 wk. Plasma and LDL antioxidant concentrations and LDL oxidizability were assessed at both 0 and 8 wk. Plasma and LDL concentrations of alpha-tocopherol were significantly increased in the supplemented group only. Compared with the placebo group, the alpha-tocopherol-supplemented group had significant reductions in LDL oxidizability at 8 wk, as shown by the time-course curves of conjugated diene and lipid peroxide formation. Also, alpha-tocopherol supplementation produced a significant prolongation in the lag phases of both assays, which was evident in both the NIDDM and IDDM subgroups. However, there were no significant changes in glycated hemoglobin or in glycated plasma proteins after alpha-tocopherol supplementation. Thus, alpha-tocopherol supplementation may be beneficial in reducing LDL oxidizability in patients with diabetes.

RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. Publishing Authors By Initials

CJ Fuller,M Chandalia,A Garg,SM Grundy,I Jialal,

For similar heterocyclic compounds: heterocyclic compounds, 2-ring: benzopyrans: vitamin e: tocopherols: alpha-tocopherol research abstracts see: heterocyclic compounds: heterocyclic compounds, 2-ring: benzopyrans: vitamin e: tocopherols: alpha-tocopherol research

PUBMED ID PMID:

MEDLINE DATE:

RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: The American journal of clinical nutrition

VOLUME: 63

Page Numbers: 753-9

Journal Abbreviation: Am. J. Clin. Nutr.

ISSN: 0002-9165

DAY: 19

MONTH: May

YEAR: 1996

RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 376027

RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. Keywords Mesh Terms:

KEYWORDS: alpha-Tocopherol

MESH TERMS: analogs & derivatives

Chemical & Substance for Abstract: RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. Information

Substance Name: tocopherol acetate

Registry Number: 7695-91-2

Grant and Affiliation Information for RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus.

AFFILIATION: Center for Human Nutrition, University of Texas Southwestern Medical Center at Dallas 75235-9052, USA.

Country: UNITED STATES

AGENCY: United States NCRR

GRANT: M01-RR-006633

ACRONYM: RR

MEDLINETA: Am J Clin Nutr

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus Related Publications

• A dose-response study on the effects of purified lycopene supplementation on biomarkers of oxidative stress.
• Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop.
• C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling.
• CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers.
• Contemporary scientific insights: role of biomarkers of inflammation in cardiovascular disease/atherosclerosis.
• Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results.
• Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome.
• Editor's Perspective on Metabolic Syndrome for 2008.
• Editorial.
• Effect of high-dose {alpha}-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease.
• Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome.
• High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy.
• High-fat, energy-dense, fast-food-style breakfast results in an increase in oxidative stress in metabolic syndrome.
• Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats.
• Increased Toll-Like Receptor (TLR) 2 and TLR4 Expression in Monocytes from Patients with Type 1 Diabetes: Further Evidence of a Proinflammatory State.
• Oxidative stress and atherosclerosis.
• RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus.
• Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome.
• Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.
• Statins and biomarkers of inflammation.
• The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells.
• The effect of weight loss and dietary fatty acids on inflammation.
• Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity.